<DOC>
	<DOCNO>NCT02046395</DOCNO>
	<brief_summary>The purpose study study effect block renin angiotensin system urinary free light chain excretion compare urine microalbumin creatinine ratio subject type 2 diabetes . The long term goal assess urinary free-light chain biomarker earlier detection kidney function impairment subject diabetes mellitus .</brief_summary>
	<brief_title>Effect Renin-angiotensin-system Blockade Urinary Free Light Chains Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Free light chain ( FLCs ) low-molecular-mass molecule ( kappa lambda light chain ) , by-product normal immunoglobulin synthesis normally excrete kidney . Presence light chain urine marker tubular dysfunction . In patient impaired kidney function , serum concentration urinary excretion polyclonal FLCs note increase . Increased excretion FLCs low-molecular weight protein [ cystatin C , NGAL ] urine may contribute progression chronic kidney disease . Higher Cystatin C demonstrate related development albuminuria . Neutrophil gelatinase-associated lipcalin ( NGAL ) excretion urine marker tubular injury kidney show elevated subject type 1 2 diabetes mellitus ( DM ) . Angiotensin-converting enzyme inhibitor ( Ace Inh ) angiotensin II receptor blocker ( ARB ) class drug renoprotective nature first line therapy treatment diabetic nephropathy . There longitudinal data evaluate effect Ace Inh ARB class drug urinary FLCs ( UFLCs ) . Our hypothesis UFLCs increase patient DM without kidney disease treatment Ace Inh and/or ARB decrease UFLCs patient . Additionally , explore change low molecular weight protein [ cystatin C , NGAL ] response treatment Ace Inh ARB .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<mesh_term>Terazosin</mesh_term>
	<criteria>Type 2 Diabetes Hypertension Estimated glomerular filtration rate ( eGFR ) &gt; 30 ml/min Use Ace Inh ARB control blood pressure willing placed alternate drug ( ) washout period blood pressure control Pregnancy Patients chronic kidney disease stage eGFR &lt; 30 ml/min ( CKD stage IV V ) Nephrotic range proteinuria ( urinary protein &gt; 3.5 gm/day ) History renal transplantation History multiple myeloma Known history hypersensitivity reaction intolerability Ace Inh ARB .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Hypertension</keyword>
</DOC>